Sanofi (SAN) Stock Overview

Engages in the research, development, manufacture, and marketing of therapeutic solutions. More details

SAN fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	2/6
Past Performance	4/6
Financial Health	6/6
Dividends	5/6

Rewards

Trading at 50.2% below our estimate of its fair value

Earnings are forecast to grow 9.79% per year

Earnings grew by 73.6% over the past year

Pays a reliable dividend of 4.52%

Risk Analysis

Shares are highly illiquid

SAN Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View Stock Community

Hoth Therapeutics

100% Patient Improvement in trial puts this $16M Biotech on the radar

Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.

132

US$5.3

70.2% undervalued

Jolt_Communications Fair Value

Revenue growth

N/A

Profit Margin

30%

Future PE

20x

Share price in 2030

US$0

Sanofi Competitors

Price History & Performance

Summary of share price highs, lows and changes for Sanofi
Historical stock prices
Current Share Price	€11.05
52 Week High	€11.05
52 Week Low	€10.02
Beta	0.44
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	9.41%

Recent updates

Shareholder Returns

	SAN	CA Pharmaceuticals	CA Market
7D	8.0%	16.5%	1.6%
1Y	n/a	-13.6%	22.2%

Return vs Industry: Insufficient data to determine how SAN performed against the Canadian Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how SAN performed against the Canadian Market.

Price Volatility

Is SAN's price volatile compared to industry and market?
SAN volatility
SAN Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	12.9%
Market Average Movement	9.2%
10% most volatile stocks in CA Market	19.7%
10% least volatile stocks in CA Market	2.9%

Stable Share Price: SAN's share price has been volatile over the past 3 months compared to the Canadian market.

Volatility Over Time: Insufficient data to determine SAN's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1994	82,878	Paul Hudson	www.sanofi.com

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, that includes hepatitis A, typhoid, yellow fever, and rabies vaccines.

Sanofi Fundamentals Summary

How do Sanofi's earnings and revenue compare to its market cap?
SAN fundamental statistics
Market cap	CA$173.01b
Earnings (TTM)	CA$10.46b
Revenue (TTM)	CA$74.92b

16.5x

P/E Ratio

2.3x

P/S Ratio

Is SAN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SAN income statement (TTM)
Revenue	€45.74b
Cost of Revenue	€13.12b
Gross Profit	€32.62b
Other Expenses	€26.24b
Earnings	€6.38b

Last Reported Earnings

Jun 30, 2025

Next Earnings Date

Oct 24, 2025

Earnings per share (EPS)	5.25
Gross Margin	71.32%
Net Profit Margin	13.96%
Debt/Equity Ratio	29.2%

How did SAN perform over the long term?

See historical performance and comparison

Dividends

4.5%

Current Dividend Yield

76%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/10/05 23:26
End of Day Share Price	2025/10/03 00:00
Earnings	2025/06/30
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Sanofi is covered by 72 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Kamla Singh	AlphaValue
John Eade	Argus Research Company
Odile Rundquist	Baader Helvea Equity Research

SanofiNEOE:SAN Stock Report